{
    "root": "d0d5f407-4f69-4e03-b101-3f42e2017f12",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Lamotrigine",
    "value": "20250516",
    "ingredients": [
        {
            "name": "LAMOTRIGINE",
            "code": "U3H27498KS"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C YELLOW NO. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        }
    ],
    "indications": "lamotrigine extended-release tablets indicated : adjunctive therapy primary generalized tonic-clonic seizures ( pgtc ) partial-onset seizures without secondary generalization patients aged 13 years older . ( 1.1 ) conversion monotherapy patients aged 13 years older partial-onset seizures receiving treatment single antiepileptic . ( 1.2 ) limitation : safety effectiveness patients younger 13 years established . ( 1.3 )",
    "contraindications": "lamotrigine extended-release tablets taken daily , without food . tablets must swallowed whole must chewed , crushed , divided .",
    "warningsAndPrecautions": "lamotrigine extended-release tablets usp , 25 mg , supplied yellow , round shaped , film-coated tablets debossed “ ” “ 949 ” one side plain side . available follows : bottles 30 : ndc 65162-949-03 bottles 90 : ndc 65162-949-09 lamotrigine extended-release tablets usp , 50 mg , supplied green , round shaped , film-coated tablets debossed “ ” “ 956 ” one side plain side . available follows : bottles 30 : ndc 65162-956-03 bottles 90 : ndc 65162-956-09 lamotrigine extended-release tablets usp , 100 mg , supplied beige , round shaped , film-coated tablets debossed “ ” “ 958 ” one side plain side . available follows : bottles 30 : ndc 65162-958-03 bottles 90 : ndc 65162-958-09 lamotrigine extended-release tablets usp , 200 mg , supplied blue , round shaped , film-coated tablets debossed “ ” “ 986 ” one side plain side . available follows : bottles 30 : ndc 65162-986-03 bottles 90 : ndc 65162-986-09 lamotrigine extended-release tablets usp , 250 mg , supplied purple , capsule shaped , film-coated tablets debossed “ 988 ” one side plain side . available follows : bottles 30 : ndc 65162-988-03 bottles 90 : ndc 65162-988-09 lamotrigine extended-release tablets usp , 300 mg , supplied gray , capsule shaped , film-coated tablets debossed “ 990 ” one side plain side . available follows : bottles 30 : ndc 65162-990-03 bottles 90 : ndc 65162-990-09 storage store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "lamotrigine extended-release tablets contraindicated patients demonstrated hypersensitivity ( e.g . , rash , angioedema , acute urticaria , extensive pruritus , mucosal ulceration ) ingredients [ boxed warning , ( 5.1 , 5.3 ) ] .",
    "indications_original": "Lamotrigine extended-release tablets are indicated for: adjunctive therapy for primary generalized tonic-clonic seizures (PGTC) and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. (1.1) conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug. (1.2) Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. (1.3)",
    "contraindications_original": "Lamotrigine extended-release tablets are taken once daily, with or without food. Tablets must be swallowed whole and must not be chewed, crushed, or divided.",
    "warningsAndPrecautions_original": "Lamotrigine extended-release tablets USP, 25 mg, are supplied as yellow, round shaped, film-coated tablets debossed with “A” above “949” on one side and plain on the other side. They are available as follows:\n                  Bottles of 30:                          NDC 65162-949-03 Bottles of 90:                          NDC 65162-949-09 \n                  Lamotrigine extended-release tablets USP, 50 mg, are supplied as green, round shaped, film-coated tablets debossed with “A” above “956” on one side and plain on the other side. They are available as follows:\n                  Bottles of 30:                          NDC 65162-956-03 Bottles of 90:                          NDC 65162-956-09 \n                  Lamotrigine extended-release tablets USP, 100 mg, are supplied as beige, round shaped, film-coated tablets debossed with “A” above “958” on one side and plain on the other side. They are available as follows:\n                  Bottles of 30:                          NDC 65162-958-03 Bottles of 90:                          NDC 65162-958-09 \n                  Lamotrigine extended-release tablets USP, 200 mg, are supplied as blue, round shaped, film-coated tablets debossed with “A” above “986” on one side and plain on the other side.  They are available as follows:\n                  Bottles of 30:                          NDC 65162-986-03 Bottles of 90:                          NDC 65162-986-09 \n                  Lamotrigine extended-release tablets USP, 250 mg, are supplied as purple, capsule shaped, film-coated tablets debossed with “AN 988” on one side and plain on the other side.  They are available as follows:\n                  Bottles of 30:                          NDC 65162-988-03 Bottles of 90:                          NDC 65162-988-09 \n                  Lamotrigine extended-release tablets USP, 300 mg, are supplied as gray, capsule shaped, film-coated tablets debossed with “AN 990” on one side and plain on the other side.  They are available as follows:\n                  Bottles of 30:                          NDC 65162-990-03 Bottles of 90:                          NDC 65162-990-09 \n                  \n                     Storage\n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Lamotrigine extended-release tablets are contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients [see Boxed Warning, Warnings and Precautions (5.1, 5.3)]."
}